Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.37	$2.22	$0.95 ▼ $2.85	$21.27M	0.13	153,406 shs	49,738 shs
CVKD Cadrenal Therapeutics	$11.15 +5.4%	$12.25	$5.70 ▼ $22.90	$22.82M	0.93	27,991 shs	27,326 shs
FRTX Fresh Tracks Therapeutics	$0.94 -0.5%	$0.94	$0.03 ▼ $1.03	$5.59M	0.54	2,709 shs	2,402 shs
RVPH Reviva Pharmaceuticals	$0.41 -5.0%	$0.54	$0.30 ▼ $4.28	$19.54M	-0.05	2.52 million shs	1.94 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	0.00%	-1.25%	+3.49%	+89.60%	-3.85%
CVKD Cadrenal Therapeutics	0.00%	+7.94%	-14.23%	-21.75%	+1,114,999,900.00%
FRTX Fresh Tracks Therapeutics	0.00%	0.00%	0.00%	0.00%	+6.25%
RVPH Reviva Pharmaceuticals	0.00%	-6.54%	+3.85%	-50.34%	-49.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AYTU Aytu BioPharma	3.1705 of 5 stars	3.5	2.0	0.0	3.4	0.6	0.0	0.6
CVKD Cadrenal Therapeutics	2.2838 of 5 stars	3.5	3.0	0.0	0.0	1.1	1.7	0.6
FRTX Fresh Tracks Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	2.6186 of 5 stars	3.6	2.0	0.0	0.0	1.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	3.00	Buy	$10.00	321.94% Upside
CVKD Cadrenal Therapeutics	3.00	Buy	$32.00	187.00% Upside
FRTX Fresh Tracks Therapeutics	0.00	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	3.29	Buy	$9.00	2,110.76% Upside

Current Analyst Ratings Breakdown

Latest FRTX, CVKD, AYTU, and RVPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	AYTU Aytu BioPharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/30/2025	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/27/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/20/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $3.00
5/16/2025	CVKD Cadrenal Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$81M	0.26	N/A	N/A	$4.64 per share	0.51
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$4.17 per share	N/A
FRTX Fresh Tracks Therapeutics	$10.06M	0.56	N/A	N/A	$1.66 per share	0.56
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	9/25/2025 (Estimated)
CVKD Cadrenal Therapeutics	-$10.65M	-$9.26	N/A	N/A	N/A	N/A	-244.94%	-181.94%	8/13/2025 (Estimated)
FRTX Fresh Tracks Therapeutics	-$5.69M	-$1.41	N/A	∞	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.79	N/A	N/A	N/A	N/A	N/A	-302.31%	8/13/2025 (Estimated)

Latest FRTX, CVKD, AYTU, and RVPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	CVKD Cadrenal Therapeutics	-$1.60	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	RVPH Reviva Pharmaceuticals	-$0.15	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	RVPH Reviva Pharmaceuticals	-$0.21	-$0.13	+$0.08	-$0.13	N/A	N/A
5/14/2025	Q3 2025	AYTU Aytu BioPharma	-$0.17	$0.20	+$0.37	$0.21	$13.74 million	$18.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
FRTX Fresh Tracks Therapeutics	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.03	0.87
CVKD Cadrenal Therapeutics	N/A	4.32	4.32
FRTX Fresh Tracks Therapeutics	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	0.54	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
CVKD Cadrenal Therapeutics	7.92%
FRTX Fresh Tracks Therapeutics	25.04%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	3.60%
CVKD Cadrenal Therapeutics	26.09%
FRTX Fresh Tracks Therapeutics	0.23%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	160	8.98 million	8.65 million	Not Optionable
CVKD Cadrenal Therapeutics	4	2.05 million	1.51 million	Not Optionable
FRTX Fresh Tracks Therapeutics	20	5.97 million	5.96 million	Not Optionable
RVPH Reviva Pharmaceuticals	5	48.00 million	34.96 million	Optionable

FRTX, CVKD, AYTU, and RVPH Headlines

Recent News About These Companies

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.com

June 29, 2025 | investing.com

Reviva Dives on Stock Offering

June 26, 2025 | baystreet.ca

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

June 26, 2025 | globenewswire.com

Reviva Pharmaceuticals stock falls after announcing public offering

June 25, 2025 | za.investing.com

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.comS

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)

May 4, 2025 | theglobeandmail.com

Reviva to Participate in the Citizens Life Sciences Conference

April 29, 2025 | finance.yahoo.com

RVPH: M&A Deals Highlight Brilaroxazine Value

April 7, 2025 | finance.yahoo.com

Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)

April 5, 2025 | markets.businessinsider.com

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

March 31, 2025 | markets.businessinsider.com

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

March 30, 2025 | globenewswire.com

Why Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) Stock Is Down 10.61%

March 7, 2025 | aaii.comA

Unusually active option classes on open February 12th

February 12, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRTX, CVKD, AYTU, and RVPH Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$2.37 0.00 (0.00%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.35 -0.02 (-1.05%)

As of 08/8/2025 07:08 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Cadrenal Therapeutics NASDAQ:CVKD

$11.15 +0.57 (+5.39%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$11.04 -0.11 (-0.99%)

As of 08/8/2025 07:07 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Fresh Tracks Therapeutics NASDAQ:FRTX

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.41 -0.02 (-5.04%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.41 +0.00 (+0.22%)

As of 08/8/2025 07:56 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time